查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球患者腫瘤組織移植模型市場規模,份額和趨勢分析：按腫瘤類型(肺,胰腺),模型類型(大鼠,小鼠),用戶(製藥和生物製藥公司,CRO,CDMO),細分市場預測2022-2030
市場調查報告書
商品編碼
1171007

全球患者腫瘤組織移植模型市場規模,份額和趨勢分析：按腫瘤類型(肺,胰腺),模型類型(大鼠,小鼠),用戶(製藥和生物製藥公司,CRO,CDMO),細分市場預測2022-2030

Patient-derived Xenograft Model Market Size, Share & Trends Analysis Report By Tumor Type (Lung, Pancreatic), By Model Type (Rats, Mice), By End-user (Pharma & Biopharma Companies, CROs, CDMOs), And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 275 Pages | 商品交期: 2-10個工作天內

價格

全球吸入和鼻腔產品合同製造服務提供商市場規模到 2030 年將達到 6.614 億美元，預計從 2022 年到 2030 年的複合年增長率為 12.8%。

癌症發病率的上升推動了對新治療方案的需求，以及全球對個性化治療的巨大需求正在推動市場增長。

本報告研究了全球患者腫瘤組織移植模型市場，並提供了包括市場前景、市場分析和競爭格局在內的全面信息。

內容

第一章調查方法及範圍

  • 市場細分和範圍
    • 腫瘤類型
    • 模型類型
    • 最終用戶
    • 區域範圍
  • 調查方法
  • 信息採購
    • 購買的數據庫
    • GVR 內部數據庫
    • 次要信息
    • 初步調查
  • 信息或數據分析
    • 數據分析模型
  • 市場製定和驗證
  • 模型詳細信息
    • 商品流分析(模型 1)
    • 批量價格分析(模型 2)
  • 二級信息列表
  • 主要信息列表
  • 目的

第 2 章執行摘要

  • 市場前景

第 3 章患者腫瘤組織移植模型市場變量、趨勢和範圍

  • 市場系列展望
    • 母公司的市場前景
    • 相關/子公司市場前景
  • 描繪滲透率和增長前景
  • 市場動態
    • 市場驅動因素分析
      • 癌症在全球範圍內繼續增加
      • 增加癌症研發投資
      • 全球對個性化護理的需求
    • 市場製約因素分析
      • 用於個性化治療的 PDX 模型成本高
      • 對動物模型的使用有嚴格的規定
    • 描繪滲透率和增長前景
    • COVID-19 的影響和恢復分析
    • 對主要交易和戰略聯盟的分析
    • 行業分析 - 波特五力分析
    • PESTLE 分析

第 4 章患者腫瘤組織移植模型市場：腫瘤類型細分分析

  • 患者腫瘤組織移植模型市場：定義和範圍
  • 患者腫瘤組織移植模型市場：按腫瘤類型劃分的市場份額分析(2021 年和 2030 年)
    • 肺癌
    • 胰腺癌
    • 前列腺癌
    • 乳腺癌
    • 其他癌症

第 5 章患者腫瘤組織移植模型市場：模型類型細分分析

  • 患者腫瘤組織移植模型市場：定義和範圍
  • 患者腫瘤組織移植模型市場：按模型類型劃分的市場份額分析(2021 年和 2030 年)
    • 鼠標
    • 大鼠

第 6 章患者腫瘤組織移植模型市場：最終用戶細分分析

  • 患者腫瘤組織移植模型市場：定義和範圍
  • 患者腫瘤組織移植模型市場：最終用戶市場份額分析(2021 年和 2030 年)
    • 製藥和生物製藥公司
    • 學術和研究機構
    • CRO□CDMO

第 7 章患者腫瘤組織移植模型市場：區域分析

  • 患者腫瘤組織移植模型：區域市場份額分析(2021 年和 2030 年)
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 意大利
    • 西班牙
      • 西班牙患者腫瘤組織移植模型市場(百萬美元)(2018-2030 年)
    • 法國
      • 法國患者腫瘤組織移植模型市場(百萬美元)(2018-2030 年)
  • 亞太地區
    • 亞太地區患者腫瘤組織移植模型市場(百萬美元)(2018-2030 年)
    • 中國
    • 印度
      • 印度患者腫瘤組織移植模型市場(百萬美元)(2018-2030 年)
    • 日本
      • 日本患者腫瘤組織移植模型市場，2018-2030 年(百萬美元)
    • 澳大利亞
      • 澳大利亞患者腫瘤組織移植模型市場(百萬美元)(2018-2030 年)
  • 拉丁美洲
    • 拉丁美洲患者腫瘤組織移植模型市場(百萬美元)(2018-2030 年)
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 南阿拉伯
    • 阿拉伯聯合酋長國

第八章競爭格局

  • 患者腫瘤組織移植模型：公司市場份額分析(2021 年和 2030 年)
  • 公司簡介
    • Charles River Laboratories
    • The Jackson Laboratory
    • Crown Bioscience
    • Altogen Labs
    • Envigo
    • WuxiAppTec
    • Oncodesign
    • Hera Biolabs
    • XenTech
    • Abnova Corporation
Product Code: GVR-4-68040-002-0

Patient-derived Xenograft Model Market Growth & Trends:

The global patient-derived xenograft model market size is expected to reach USD 661.4 million by 2030, registering a CAGR of 12.8% over the forecast years according to a new report by Grand View Research, Inc. Growing burden of cancer, which is promoting the demand for new treatment options, along with significant demand for personalized therapies worldwide will boost the growth of the industry. Patient-derived Xenograft (PDX) models have garnered increasing awareness during the past decade. These types are typically characterized by the introduction of fresh immunodeficient mice with patient-derived tumor tissues. These models have been used with efficacy in preclinical studies to identify prospective biomarkers for drug response and resistance, as well as to monitor the development of tumors in therapy response. The concept of a co-clinical study, which involves using several models at once-referred to as "Avatar models"-has recently grown in popularity and has been expanded to incorporate PDX models.

Moreover, PDX models were used in a few prospective trials to direct therapeutic therapy decisions for a limited number of patients with confirmed extended survival. The COVID-19 pandemic had a negative impact on the industry. It disrupted the clinical trials and also reduced the productivity of pharmaceutical & biopharmaceutical companies. According to research by Avantor Sciences, 70% of global clinical trials were disrupted as of July 2020. 369 trials related to oncology had been delayed in the USA alone, central nervous system trials at 223, gastrointestinal trials at 116, and cardiovascular trials at 99. Despite COVID-19, the rising number of cancer cases & increased R&D activities by pharmaceutical companies will contribute to the growth of the market. For instance, as per the GLOBOCAN Report 2020, 19.3 million new cancer cases and almost 10.0 million cancer deaths occurred in 2020. The majorly impacted cancers were breast, lung, colorectal, and prostate cancer.

Patient-derived Xenograft Model Market Report Highlights:

  • The breast cancer segment dominated the industry in 2021 due to arise in the cases of breast cancer driving the growth of the market
  • For instance, female breast cancer is expected 2.3 million new cases & has surpassed lung cancer as the most prevalent disease diagnosed
  • The mice model type segment held the highest revenue share in 2021 due to factors, such as the increasing use of the mice model for cancer treatment and ease of manipulation & procurement
  • The CROs & CDMOs end-user segment accounted for the largest share in 2021. The segment is also anticipated to witness the fastestCAGRover the forecast period
  • A growing number of pharmaceutical companies are outsourcing their preclinical studies to CROs & CDMOs, which, in turn, is driving the growth of this segment
  • North America was the largest region in 2021 due to a high number of research studies in the region, increased funding for preclinical research, and demand for innovative therapies

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Tumor Type
    • 1.1.2. Model Type
    • 1.1.3. End User
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.2. Volume price analysis (Model 2)
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2
    • 1.9.3. Objective 3
    • 1.9.4. Objective 4

Chapter 2. Executive Summary

  • 2.1. Market Outlook

Chapter 3. Patient-Derived Xenograft Model Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
      • 3.3.1.1. Growing burden of cancer across the globe
      • 3.3.1.2. Increasing R&D investment for cancer research
      • 3.3.1.3. Demand for personalized therapies worldwide
    • 3.3.2. Market restraint analysis
      • 3.3.2.1. High cost of personalized PDX models
      • 3.3.2.2. Stringent regulations towards the use of animal models
    • 3.3.3. Penetration & Growth Prospect Mapping
    • 3.3.4. Covid-19 Impact & Recovery Analysis
    • 3.3.5. Major Deals and Strategic Alliances Analysis
    • 3.3.6. Industry Analysis - Porter's
    • 3.3.7. PESTLE Analysis

Chapter 4. Patient-Derived Xenograft Model Market: Tumor Type Segment Analysis

  • 4.1. Patient-Derived Xenograft Model Market: Definition & Scope
  • 4.2. Patient-Derived Xenograft Model Market: Tumor Type Market Share Analysis, 2021 & 2030
    • 4.2.1. Lung Cancer
      • 4.2.1.1. Lung Cancer Market, 2018 - 2030 (USD Million)
    • 4.2.2. Pancreatic Cancer
      • 4.2.2.1. Pancreatic Cancer Market, 2018 - 2030 (USD Million)
    • 4.2.3. Prostate Cancer
      • 4.2.3.1. Prostate Cancer Market, 2018 - 2030 (USD Million)
    • 4.2.4. Breast Cancer
      • 4.2.4.1. Breast Cancer Market, 2018 - 2030 (USD Million)
    • 4.2.5. Other Cancer
      • 4.2.5.1. Other Cancer Market, 2018 - 2030 (USD Million)

Chapter 5. Patient-Derived Xenograft Model Market: Model Type Segment Analysis

  • 5.1. Patient-Derived Xenograft Model Market: Definition & Scope
  • 5.2. Patient-Derived Xenograft Model Market: Model Type Market Share Analysis, 2021 & 2030
    • 5.2.1. Mice
      • 5.2.1.1. Mice Market, 2018 - 2030 (USD Million)
    • 5.2.2. Rats
      • 5.2.2.1. Rats Market, 2018 - 2030 (USD Million)

Chapter 6. Patient-Derived Xenograft Model Market: End-user Segment Analysis

  • 6.1. Patient-Derived Xenograft Model Market: Definition & Scope
  • 6.2. Patient-Derived Xenograft Model Market: End User Market Share Analysis, 2021 & 2030
    • 6.2.1. Pharmaceutical & Biopharmaceutical Companies
      • 6.2.1.1. Pharmaceutical & Biopharmaceutical Companies Market, 2018 - 2030 (USD Million)
    • 6.2.2. Academic & Research Institutes
      • 6.2.2.1. Academic & Research Institutes Market, 2018 - 2030 (USD Million)
    • 6.2.3. CROs & CDMOs
      • 6.2.3.1. CROs & CDMOs Market, 2018 - 2030 (USD Million)

Chapter 7. Patient-Derived Xenograft Model Market: Regional Analysis

  • 7.1. Patient-Derived Xenograft Model: Regional market share analysis, 2021 & 2030
  • 7.2. North America
    • 7.2.1. U.S. Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.3.2. U.K.
      • 7.3.2.1. U.K. Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.3.4. Italy
      • 7.3.4.1. Italy Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.3.5. Spain
      • 7.3.5.1. Spain Patient-Derived Xenograft Model Market, 2018 - 2030(USD Million)
    • 7.3.6. France
      • 7.3.6.1. France Patient-Derived Xenograft Model Market, 2018 - 2030(USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Patient-Derived Xenograft Model Market, 2018 - 2030(USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.4.3. India
      • 7.4.3.1. India Patient-Derived Xenograft Model Market, 2018 - 2030(USD Million)
    • 7.4.4. Japan
      • 7.4.4.1. Japan Patient-Derived Xenograft Model Market, 2018 - 2030(USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Australia Patient-Derived Xenograft Model Market, 2018 - 2030(USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Patient-Derived Xenograft Model Market, 2018 - 2030(USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Mexico Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.5.4. Argentina
      • 7.5.4.1. Argentina Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
  • 7.6. MEA
    • 7.6.1. MEA Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.6.3. South Arabia
      • 7.6.3.1. South Africa Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Patient-Derived Xenograft Model: Company market share analysis, 2021 & 2030
  • 8.2. Company Profiles
    • 8.2.1. Charles River Laboratories
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Service benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. The Jackson Laboratory
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Service benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. Crown Bioscience
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Service benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Altogen Labs
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Service benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Envigo
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Service benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. WuxiAppTec
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Service benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Oncodesign
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Service benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. Hera Biolabs
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Service benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. XenTech
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Service benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. Abnova Corporation
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Service benchmarking
      • 8.2.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary sources
  • Table 2 List of Abbreviations

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 QFD modeling for market share assessment
  • Fig. 6 Market formulation & validation
  • Fig. 7 Commodity flow analysis
  • Fig. 8 Volume price analysis
  • Fig. 9 Patient-derived xenograft model market snapshot (2021)
  • Fig. 10 Patient-derived xenograft model market segmentation
  • Fig. 11 Heat map analysis
  • Fig. 12 Parent market outlook
  • Fig. 13 Ancillary market outlook
  • Fig. 14 Penetration & growth prospect mapping
  • Fig. 15 Market driver relevance analysis (Current & future impact)
  • Fig. 16 Market restraint relevance analysis (Current & future impact)
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 19 Patient-derived xenograft model market tumor type outlook: Segment dashboard
  • Fig. 20 Patient-derived xenograft model market: tumor type movement analysis
  • Fig. 21 Lung cancer market, 2018 - 2030 (USD Million)
  • Fig. 22 Pancreatic cancer market, 2018 - 2030 (USD Million)
  • Fig. 23 Prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 24 Breast cancer market, 2018 - 2030 (USD Million)
  • Fig. 25 Other cancer market, 2018 - 2030 (USD Million)
  • Fig. 26 Patient-derived xenograft model market model type outlook: Segment dashboard
  • Fig. 27 Patient-derived xenograft model market: model type movement analysis
  • Fig. 28 Mice market, 2018 - 2030 (USD Million)
  • Fig. 29 Rats market, 2018 - 2030 (USD Million)
  • Fig. 30 Patient-derived xenograft model market end-user outlook: Segment dashboard
  • Fig. 31 Patient-derived xenograft model market: End user movement analysis
  • Fig. 32 Pharmaceutical & Biopharmaceutical companies market, 2018 - 2030 (USD Million)
  • Fig. 33 Academic & research institutes market, 2018 - 2030 (USD Million)
  • Fig. 34 CROs & CDMOs market, 2018 - 2030 (USD Million)
  • Fig. 35 Regional market: Key takeaways
  • Fig. 36 Patient-derived xenograft model market: Regional movement analysis
  • Fig. 37 North America. market, 2018 - 2030 (USD Million)
  • Fig. 38 U.S. market, 2018 - 2030 (USD Million)
  • Fig. 39 Canada market, 2018 - 2030 (USD Million)
  • Fig. 40 Europe market, 2018 - 2030 (USD Million)
  • Fig. 41 U.K. market, 2018 - 2030 (USD Million)
  • Fig. 42 Germany market, 2018 - 2030 (USD Million)
  • Fig. 43 France market, 2018 - 2030 (USD Million)
  • Fig. 44 Italy market, 2018 - 2030 (USD Million)
  • Fig. 45 Spain market, 2018 - 2030 (USD Million)
  • Fig. 46 Asia Pacific market, 2018 - 2030 (USD Million)
  • Fig. 47 Japan market, 2018 - 2030 (USD Million)
  • Fig. 48 China market, 2018 - 2030 (USD Million)
  • Fig. 49 India market, 2018 - 2030 (USD Million)
  • Fig. 50 Australia market, 2018 - 2030 (USD Million)
  • Fig. 51 Latin America market, 2018 - 2030 (USD Million)
  • Fig. 52 Brazil market, 2018 - 2030 (USD Million)
  • Fig. 53 Mexico market, 2018 - 2030 (USD Million)
  • Fig. 54 Argentina market, 2018 - 2030 (USD Million)
  • Fig. 55 MEA market, 2018 - 2030 (USD Million)
  • Fig. 56 South Africa market, 2018 - 2030 (USD Million)
  • Fig. 57 Saudi Arabia market, 2018 - 2030 (USD Million)
  • Fig. 58 UAE market, 2018 - 2030 (USD Million)